Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ICML 2023 and Follicular Lymphoma View overview page

Follicular lymphoma: the value of immunotherapies & other exciting areas of research

Mitch Smith • 15 Jun 2023

The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trials

Graham Collins • 16 Jun 2023

CC-99282 ± rituximab for R/R NHL: Phase I/II trial interim analysis

Jean-Marie Michot • 16 Jun 2023

Work of the Follicular Lymphoma Foundation

Mitch Smith • 15 Jun 2023

TNB-486: interim results of a CD19/CD3 T-cell engager in R/R follicular lymphoma

Ranjit Nair • 16 Jun 2023

The prognostic role of MRD in follicular lymphoma

Simone Ferrero • 15 Jun 2023

Diagnosis and staging of follicular lymphoma

Simone Ferrero • 15 Jun 2023

FOLL12: MRD and PET as prognostic tools for follicular lymphoma

Simone Ferrero • 15 Jun 2023

OLYMPIA-5: odronextamab + lenalidomide for R/R indolent lymphoma

Umberto Vitolo • 15 Jun 2023

Epigenetic regulation of immune microenvironment interactions in lymphoma

Michael Green • 14 Jun 2023

Exploring the impact of magnesium levels on the outcomes of patients with LBCL receiving axi-cel

Patrizia Mondello • 16 Jun 2023

ETCTN P10500: a Phase I/expansion study of tazemetostat plus belinostat for R/R NHL

Jennifer Amengual • 15 Jun 2023

Using patient-derived organoids to investigate bispecific T-cell engager immunotherapy in FL

Joseph Schroers-Martin • 15 Jun 2023

15-year follow-up of SWOG-S0016: achieving a functional cure in a subset of patients with FL

Mazyar Shadman • 9 Jun 2023

The future of bispecific antibodies in the treatment and management of R/R follicular lymphoma

Graham Collins • 16 Jun 2023

The importance of better understanding the genomic landscape of follicular lymphoma

Pablo Mozas • 16 Jun 2023

1
2
Next